BSE: AARTIDRUGS - Aarti Drugs Limited

六个月盈利: -21.16%
股息率: +0.19%

促销时间表 Aarti Drugs Limited


关于公司 Aarti Drugs Limited

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally.

更多详情
The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, moxifloxacin, norfloxacin, ofloxacin, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, benzene sulphonic acid methyl ester, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for the antioxidant, antifungal, cardiovascular, and antidiabetic therapeutic areas. The company was incorporated in 1984 and is headquartered in Mumbai, India.

ISIN INE767A01016
Industry Pharmaceuticals
Sector Health Care
Валюта inr
Валюта отчета inr
Див.доход ао 0.1895
Дивиденд ао 1
Сайт https://www.aartidrugs.co.in
Цена ао 422.65
每日价格变化: -0.5915% (422.65)
每周价格变化: -7.97% (456.55)
每月价格变化: -5.57% (444.95)
3个月内价格变化: -16.81% (505.05)
六个月内的价格变化: -21.16% (532.9)
每年价格变化: -21.08% (532.35)
3年内价格变化: -20.53% (528.7)
5年内价格变化: -19.25% (520.3)
10年价格变化: 0% (420.15)
年初以来价格变化: -5.52% (444.7)

低估

姓名 意义 年级
P/S 1.66 8
P/BV 3.27 5
P/E 24.43 6
EV/EBITDA 12.94 7
全部的: 6.75

效率

姓名 意义 年级
ROA, % 7.06 2
ROE, % 13.86 4
全部的: 3.67

股息

姓名 意义 年级
Div yield, % 0.1895 0.48
DSI 0.9286 9.29
全部的: 1.61

责任

姓名 意义 年级
Debt/EBITDA 1.83 7
全部的: 7.4

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 40 6
盈利能力 Ebitda, % 44.13 6
盈利能力 EPS, % -43.02 0
全部的: 3.2

ETF 分享, % 本年盈利能力, % 股息, %
iShares MSCI India Small-Cap ETF 0.05202 0.4625 0.96163
WisdomTree India Earnings Fund 0.03922 5.23 1.65591
SPDR S&P Emerging Markets Small Cap ETF 0.02285 5.46 3.03583
iShares MSCI Emerging Markets Small-Cap ETF 0.02276 7.67 2.7853
Dimensional Emerging Markets Core Equity 2 ETF 0.00727 15.96 3.34087
SPDR Portfolio MSCI Global Stock Market ETF 0.00571 17.99 2.19607
Avantis Emerging Markets Equity ETF 0.00091 8.77 3.60513
SPDR Portfolio Emerging Markets ETF 0.0009 11.59 3.1879

导师 职称 支付 出生年份
Mr. Prakash Moreshwar Patil Chairman, MD, CEO & Head of BR 27.65M 1947 (78 年)
Mr. Harshit Manila Savla Joint MD & Executive Director 25.55M 1962 (63 年)
Mr. Harit Pragji Shah Whole-Time Director 25.55M 1963 (62 年)
Mr. Uday Moreshwar Patil Whole-Time Director 3.19M 1963 (62 年)
Mr. Rashesh Chandrakant Gogri MD & Executive Director 25.55M 1974 (51 年)
Mr. Adhish Prakash Patil CFO & COO N/A 1983 (42 年)
Mr. Dhanaji L. Kakade Vice President of Technical N/A
Mr. Vishwa Harshit Savla Managing Director of the Pinnacle Life Science Private Limited N/A
Mr. Rushikesh Vivek Deole Company Secretary & Compliance Officer N/A

地址: India, Mumbai, Mahendra Industrial Estate - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.aartidrugs.co.in